Actionable insights straight to your inbox

Equities logo

Gritstone Oncology Signs R&D Deal with bluebird bio and Files for $80 Million IPO

bluebird bio to pay $30 million upfront for 10 of Gritstone's tumor-specific targets and T-cell receptors (Image: Gritstone Oncology).
Cambridge, Massachusetts-based bluebird bio (BLUE) soared to an all-time intraday high in Monday action after releasing positive preliminary clinical trial data for its experimental gene therapy